Antiviral Drugs (eBook)

From Basic Discovery Through Clinical Trials

Wieslaw M. Kazmierski (Autor)

eBook Download: PDF

2011
John Wiley & Sons (Verlag)
978-0-470-92934-6 (ISBN)

Infos

This book focuses on new small molecule approaches to combat viral infections. The chapters describe the discovery and development from bench through the clinic of relatively recently-approved antiviral drugs and compounds in advanced clinical development. Organized by a virus (such as HIV, HCV, RSV, influenza, HBV and CMV) and written by top academic and industrial authorities in the field, the book provides a unique opportunity to study, understand and apply discovery and development principles and learning without the need for an individual to research, analyze and synthesize all immense sourcing references.  Topics showcase challenges and solutions of issues encountered, offering tremendous experience accumulated over many years of research that will be particularly useful to basic and bench scientists as well as clinicians as they continue discovering and developing new drugs and therapies.

WIESLAW M. KAZMIERSKI, PhD, has worked on novel HIV and HCV therapies in both small and large pharma settings for the last two decades, helping to advance molecules to clinical trials. Dr. Kazmierski has authored numerous peer-reviewed publications and has been named a co-inventor on many patents. He has edited scientific books and had served on journal editorial boards.

Inhalt

ANTIVIRAL DRUGS 3
CONTENTS 7
CONTRIBUTORS 11
PREFACE 15
PART I HUMAN IMMUNODEFICIENCY VIRUS 17
Section I HIV Protease Inhibitors 1
1 Discovery and Development of Atazanavir 19
2 Discovery and Development of PL-100, A Novel HIV-1 Protease Inhibitor 35
3 Darunavir (Prezista, TMC114): From Bench to Clinic, Improving Treatment Options for HIV-Infected Patients 47
4 Discovery and Development of Tipranavir 63
Section II HIV Non-nucleoside Reverse Transcriptase Inhibitors 1
5 TMC278 (Rilpivirine): A Next-Generation NNRTI in Phase III Clinical Development for Treatment-Naive Patients 75
6 Etravirine: From TMC125 to Intelence: A Treatment Paradigm Shift for HIV-Infected Patients 87
Section III HIV Nucleoside Reverse Transcriptase Inhibitors 1
7 Discovery and Development of Tenofovir Disoproxil Fumarate 101
8 Discovery and Development of Apricitabine 119
Section IV HIV Entry Inhibitors 1
9 Discovery and Development of Maraviroc and PF-232798: CCR5 Antagonists for the Treatment of HIV-1 Infection 133
10 Discovery of the CCR5 Antagonist Vicriviroc (Sch 417690/Sch-D) for the Treatment of HIV-1 Infection 153
11 Discovery and Development of HIV-1 Entry Inhibitors That Target gp120 165
Section V HIV Integrase Inhibitors 1
12 Discovery of MK-0536: A Potential Second-Generation HIV-1 Integrase Strand Transfer Inhibitor with a High Genetic Barrier to Mutation 179
13 Discovery and Development of HIV Integrase Inhibitor Raltegravir 197
14 Elvitegravir: A Novel Monoketo Acid HIV-1 Integrase Strand Transfer Inhibitor 213
PART II HEPATITIS C VIRUS 223
Section VI Protease Inhibitors 1
15 Discovery and Development of Telaprevir 225
16 Discovery and Development of BILN 2061 and Follow-up BI 201335 241
17 Intervention of Hepatitis C Replication Through NS3-4A, the Protease Inhibitor Boceprevir 255
18 Discovery and Development of the HCV NS3/4A Protease Inhibitor Danoprevir (ITMN-191/RG7227) 273
19 Discovery and Development of the HCV Protease Inhibitor TMC435 289
Section VII HCV Polymerase Nucleoside Inhibitors 1
20 Discovery and Clinical Evaluation of the Nucleoside Analog Balapiravir (R1626) for the Treatment of HCV Infection 303
21 Discovery and Development of PSI-6130/RG7128 321
Section VIII Other HCV Inhibitors 1
22 Discovery of Cyclophilin Inhibitor NIM811 as a Novel Therapeutic Agent for HCV 333
23 HCV Viral Entry Inhibitors 345
PART III RESPIRATORY SYNCYTIAL VIRUS INHIBITORS 355
24 Discovery of the RSV Inhibitor TMC353121 357
25 Discovery and Development of Orally Active RSV Fusion Inhibitors 369
26 Discovery and Development of RSV604 383
PART IV INFLUENZA, HEPATITIS B, AND CYTOMEGALOVIRUS INHIBITORS 399
27 Discovery and Development of Influenza Virus Sialidase Inhibitor Relenza 401
28 Discovery and Development of Entecavir 417
29 Benzimidazole Ribonucleosides: Novel Drug Candidates for the Prevention and Treatment of Cytomegalovirus Diseases 433
INDEX 451
Color Plate 455

Produkt-Details

• Erscheint lt. Verlag: 30.6.2011
• Sprache: englisch
• Themenwelt: Medizin / Pharmazie ► Gesundheitsfachberufe
• Themenwelt: Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie
• Themenwelt: Naturwissenschaften ► Chemie
• Schlagworte: academia • across • Antiviral • Arzneimittelentwicklung • authorities • Biowissenschaften • Book • CASE • Chemie • Chemistry • compiles information • Continues • Drug • Drug Discovery & Development • Drugs • extensive • Fast • Field • Industrial • Life Sciences • Literature • Medical Science • Medizin • Microbiology & Virology • Mikrobiologie u. Virologie • One • onestop • Pharmaceutical • Pharmacology & Pharmaceutical Medicine • Pharmakologie u. Pharmazeutische Medizin • Practical • Reference • Researchers • Subject • Tackle • Tools • Virologie • Wirkstoffforschung • Wirkstoffforschung u. -entwicklung
• ISBN-10: 0-470-92934-0 / 0470929340
• ISBN-13: 978-0-470-92934-6 / 9780470929346